Results 141 to 150 of about 3,339,972 (325)

The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities

open access: yesBritish Journal of Pharmacology, EarlyView.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli   +6 more
wiley   +1 more source

The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors

open access: yes, 2012
Rimonabant (SR141716) and the structurally related AM251 are widely used in pharmacological experiments as selective cannabinoid receptor CB(1) antagonists / inverse agonists. Concentrations of 0.5-10 µM are usually applied in in vitro experiments.
Baur, R   +11 more
core   +1 more source

Natural product‐derived TRPM7 channel inhibitors in neurological injury: Mechanisms, pharmacological potential and translational challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
Disruption of intracellular ionic homeostasis is a convergent pathological feature across diverse neurological injuries and disorders, including ischaemic and haemorrhagic stroke, hypoxic–ischaemic brain injury, traumatic brain injury, epilepsy and brain tumour.
Xinyang Zhang   +5 more
wiley   +1 more source

Positive modulation of glucagon‐like peptide 1 (GLP‐1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Haemorphins act on GLP‐1 receptor (GLP‐1R) activity and signalling in a positive allosteric manner. This leads to potentiated GLP‐1‐mediated activity and signalling, as well as insulin synthesis, which may have implications for glucose metabolism and, thereby, diabetes and obesity. (The graph was created in BioRender.com).
Farheen Badrealam Khan   +13 more
wiley   +1 more source

Expression of Cannabinoid Receptors in the Trigeminal Ganglion of the Horse. [PDF]

open access: yesInt J Mol Sci, 2023
Zamith Cunha R   +7 more
europepmc   +1 more source

Targeted delivery of the CB2 receptor agonist JWH‐133 via VCAM‐1‐functionalised nanoparticles attenuates atherosclerosis and reveals sex‐specific therapeutic outcomes

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Atherosclerosis, a chronic inflammatory disease characterised by lipid accumulation and endothelial dysfunction, remains a leading cause of cardiovascular morbidity and mortality. While cannabinoid 2 (CB2) receptor agonists show therapeutic promise in preclinical studies, their systemic application is hindered by poor ...
Lucía Martín‐Navarro   +3 more
wiley   +1 more source

The fight of innate immunity and abnormal cannabinoids against Candida infection

open access: yesBritish Journal of Pharmacology, EarlyView.
Candida species represent the most clinically significant fungal pathogens in humans, with invasive candidiasis carrying a mortality of 30%–40% in critically ill patients despite modern antifungal therapy. The innate immune system – through the coordinated and specific activities of neutrophils, macrophages, NK cells, mast cells and eosinophils ...
Prince Ofori   +2 more
wiley   +1 more source

GLP‐1 receptor activation attenuates chronic migraine‐like behaviour: Sex‐specific modulation of opioid‐ and endocannabinoid‐related pathways

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Chronic migraine (CM) is a highly disabling condition that remains suboptimally treated. Metabolic disturbances may trigger migraine chronification, whereas impaired endogenous pain inhibition contributes to CM development. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), used for type 2 diabetes and obesity, show efficacy ...
Katarina Sićović   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy